News Agency
The Times

ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of 'Pemziviptadil' for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND approved by MFDS

  • Written by PR Newswire
ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of 'Pemziviptadil' for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND approved by MFDS

SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for 'Pemziviptadil (development code name PF1804),' a treatment for DMD (Duchenne Muscular Dystrophy) cardiomyopathy, from the U.S. Food and Drug Administration (FDA).

Pemziviptadil is a once-weekly DMD...

Read more: ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of 'Pemziviptadil' for DMD...

How to Choose a Local SEO Agency That Can Generate Real Enquiries, Not Just Rankings

A local SEO proposal may promise improved Google Maps visibility, extra keywords, and monthly reports. Those can be useful, but they do not automatically mean the business will receive more calls from suitable customers. Before committing to a contract, owners... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion